{
    "clinical_study": {
        "@rank": "110835", 
        "acronym": "A-GAPP", 
        "arm_group": {
            "arm_group_label": "Cisplatin-5FU-Afatinib", 
            "arm_group_type": "Experimental", 
            "description": "Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (\"Weekday on, Weekend off\") for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of the combination of\n      Cisplatin,5-Fluorouracil(5FU) and Afatinib as first-line therapy in patients with advanced\n      gastric or gastroesophageal junction cancer. The study will include 55 patients in all. The\n      patients will receive open-label Cisplatin intravenous 75mg/m2 on Day 1, 5FU 750mg/m2 at\n      24-hour intravenous infusion on Days 1-4, and Afatinib 40mg per os on Days 3-5, 8-12, 15-19.\n\n      The administration of Afatinib will start on Day 3 of each therapy cycle with an\n      administration interval on each weekend (\"Weekday on, Weekend off\") for 21 days.\n      Instructions are given on the dose reduction scheme in the presence of toxicity. The\n      administration of the combination Cisplatin-5FU-Afatinib will be continued until disease\n      progression, appearance of significant toxicity, completion of 6 treatment cycles, or\n      withdrawal of consent. At completion of 6 cycles of the combination, in the absence of\n      disease progression, the administration of Afatinib as maintenance monotherapy will be\n      continued until disease progression, appearance of significant toxicity, or withdrawal of\n      consent at the weekday on-weekend off schedule. Imaging will be applied once every 8 weeks,\n      and once every 12 weeks in the Afatinib maintenance therapy phase."
        }, 
        "brief_title": "Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastric Cancer", 
            "Gastroesophageal Junction Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histological or cytological diagnosis of gastric and/or\n             gastroesophageal junction adenocarcinoma/carcinoma.\n\n          -  Locally advanced or metastatic inoperable disease.\n\n          -  Life expectancy \u226512 weeks.\n\n          -  Patients who may have undergone any type of palliative treatment for localised\n             disease, including surgical approaches and palliative radiotherapy, but not in the\n             last four weeks before the trial.\n\n          -  Adequate bone marrow, hepatic and renal functional reserves (ANC\u22651500mm3, PLT\u2265100mm3,\n             GFR\u226550ml/min by Gault Formula, bilirubin <1.5x, Aspartate Aminotransferase\n             (AST)/Alanine Aminotransferase (ALT) <2.5x upper normal limit or 5x in the presence\n             of hepatic metastases).\n\n          -  Patients must be able to swallow pharmaceutical tablets and to be eligible to receive\n             intravenous chemotherapy.\n\n          -  Men or women patients must be at least 18 years old.\n\n          -  Performance Status Scale 0 or 1 (ECOG).\n\n          -  Measurable disease according to RECIST 1.1.\n\n          -  Left ventricular ejection fraction (LVEF) \u226550% (ECHO or MUGA).\n\n          -  Provision of patient informed consent for participation in the study and for the use\n             of biological material for research purposes.\n\n          -  Willingness and ability to comply with scheduled medical visits, therapeutic\n             treatment programmes, laboratory testing and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Previous systemic first-line therapy.\n\n          -  Previous therapy with EGFR/HER Tyrosine Kinase Inhibitor (TKI) or other experimental\n             agent.\n\n          -  Diagnosis of a second malignancy, except basal cell carcinoma of the squamous\n             epithelium or in situ carcinoma of any organ, for which an appropriate treatment has\n             been administered without indications of relapse for 12 months.\n\n          -  Presence of uncontrolled, active brain metastases (controlled brain metastases are\n             considered those that have been irradiated and have remained stable for at least 4\n             weeks after radiation therapy).\n\n          -  Diagnosis of spinal cord compression or carcinomatous meningitis.\n\n          -  Any of the following that has occurred within 12 months before the start of the study\n             treatment: myocardial infarction, serious or unstable angina pectoris,\n             aortic-coronary or peripheral bypass surgery, symptomatic heart failure, vascular\n             stroke, or transient ischemic attack, or pulmonary embolism.\n\n          -  Continuing grade \u22652 heart rate abnormalities; atrial fibrillation of any grade.\n\n          -  Hypertension uncontrolled by medication treatment (>150/100 mm/Hg despite the\n             administration of best medical therapy).\n\n          -  In the case of previous irradiation of locally advanced disease, absence of\n             measurable tumor sites outside the irradiation field.\n\n          -  Presence of any other disease which in the opinion of the doctor responsible\n             constitutes a contraindication for the administration of cisplatin, 5FU or afatinib.\n\n          -  Diagnosed human immunodeficiency virus (HIV) or disease associated with Acquired\n             Immunodeficiency Syndrome (AIDS).\n\n          -  Pregnancy or lactation. Female patients must be surgically sterilised, menopausal, or\n             must consent to use effective contraception throughout the course of the trial.All\n             female patients with reproduction ability must undergo a pregnancy test (serum or\n             urine). The effective contraceptive technique will be determined by the main\n             investigator or a person authorized by the investigator.\n\n          -  Any other serious, acute or chronic, medical or psychiatric condition or laboratory\n             analysis finding which, in the investigator's opinion, could create excessive danger\n             as regards the patient's participation in the trial or administration of the trial\n             medication may render a patient ineligible for inclusion in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743365", 
            "org_study_id": "HE7/12", 
            "secondary_id": "2011-006198-25"
        }, 
        "intervention": {
            "arm_group_label": "Cisplatin-5FU-Afatinib", 
            "intervention_name": "Cisplatin-5FU-Afatinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "chr_papadim@yahoo.gr", 
                    "last_name": "Christos Papadimitriou, Ass.Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11528"
                    }, 
                    "name": "Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens \"Alexandra\""
                }, 
                "investigator": {
                    "last_name": "Christos Papadimitriou, Ass.Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nxiros@otenet.gr", 
                    "last_name": "Nikolaos Xiros, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "12462"
                    }, 
                    "name": "Division of Oncology, 2nd Dept of Internal Medicine, University Hospital \"Attikon\""
                }, 
                "investigator": {
                    "last_name": "Nikolaos Xiros, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "e.razis@hygeia.gr", 
                    "last_name": "Evangelia Razis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "15123"
                    }, 
                    "name": "3rd Dept of Medical Oncology, Hygeia Hospital"
                }, 
                "investigator": {
                    "last_name": "Evangelia Razis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hecogiat@otenet.gr", 
                    "last_name": "Dimosthenis V. Skarlos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "18547"
                    }, 
                    "name": "2nd Dept of Medical Oncology, Metropolitan Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimosthenis V. Skarlos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "elinardou@otenet.gr", 
                    "last_name": "Elena Linardou, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "18547"
                    }, 
                    "name": "1st Dept of Medical Oncology, Metropolitan Hospital"
                }, 
                "investigator": {
                    "last_name": "Elena Linardou, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bpstudies@yahoo.gr", 
                    "last_name": "Gerassimos Aravantinos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "14564"
                    }, 
                    "name": "2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Gerassimos Aravantinos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tryf@hol.gr", 
                    "last_name": "Dimitrios Tryfonopoulos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11522"
                    }, 
                    "name": "2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimitrios Tryfonopoulos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pectasid@otenet.gr", 
                    "last_name": "Dimitrios Pectasides, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }, 
                    "name": "2nd Dept of Internal Medicine, General Hospital of Athens \"Hippokratio\""
                }, 
                "investigator": {
                    "last_name": "Dimitrios Pectasides, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "josephsgouros@yahoo.co.uk", 
                    "last_name": "Joseph Sgouros, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "14564"
                    }, 
                    "name": "3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Joseph Sgouros, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "johnsougl@gmail.com", 
                    "last_name": "Ioannis Souglakos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklio", 
                        "country": "Greece", 
                        "zip": "71110"
                    }, 
                    "name": "Dept of Medical Oncology, University Hospital of Heraklion"
                }, 
                "investigator": {
                    "last_name": "Ioannis Souglakos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gpenther@otenet.gr", 
                    "last_name": "George Pentheroudakis, Ass.Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Ioannina", 
                        "country": "Greece", 
                        "zip": "45110"
                    }, 
                    "name": "Dept of Medical Oncology, Ioannina University Hospital"
                }, 
                "investigator": {
                    "last_name": "George Pentheroudakis, Ass.Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cpapandreou@med.uth.gr", 
                    "last_name": "Christos Papandreou, Professor", 
                    "phone": "0030 2413502785"
                }, 
                "facility": {
                    "address": {
                        "city": "Larissa", 
                        "country": "Greece", 
                        "zip": "41110"
                    }, 
                    "name": "University Hospital of Larissa, Oncology Dept"
                }, 
                "investigator": {
                    "last_name": "Christos Papandreou, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maktom@yahoo.com", 
                    "last_name": "Thomas Makatsoris, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Patras", 
                        "country": "Greece", 
                        "zip": "26504"
                    }, 
                    "name": "Division of Oncology, Dept of Internal Medicine, University Hospital of Patras"
                }, 
                "investigator": {
                    "last_name": "Thomas Makatsoris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fountzil@auth.gr", 
                    "last_name": "George Fountzilas, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece", 
                        "zip": "56429"
                    }, 
                    "name": "Dept of Medical Oncology, Papageorgiou General Hospital"
                }, 
                "investigator": {
                    "last_name": "George Fountzilas, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer", 
        "overall_contact": {
            "email": "gpenther@otenet.gr", 
            "last_name": "George Pentheroudakis, Ass.Prof", 
            "phone": "0030 26510 99394"
        }, 
        "overall_official": {
            "affiliation": "Dept of Medical Oncology, Ioannina University Hospital", 
            "last_name": "George Pentheroudakis, Ass.Prof", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Greece: National Organization for Medicines", 
                "Greece: National Ethics Committee", 
                "Greece: Ministry of Health and Welfare"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Imaging will be performed once every 8 weeks during treatment with cisplatin-5FU-afatinib (6 cycles), and once every 12 weeks in the Afatinib maintenance therapy phase.", 
            "measure": "Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.", 
            "safety_issue": "No", 
            "time_frame": "At an average of 6 months for each patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "OS will be calculated from the date of treatment initiation to the date of death from any cause assessed up to 36 months."
            }, 
            {
                "measure": "Evaluation of Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "PFS will be calculated from the date of treatment initiation to the date of disease progression or date of death, assessed up to 36 months."
            }, 
            {
                "description": "Distribution of Adverse Events (AEs) according to severity grade.\nEvaluation of AEs will be performed:\nOn Day 1 and day 10 in cycle 1,on Day 1 in cycles 2-6 (every 21 days) and on Day 1 during maintenance treatment with afatinib (every 4 weeks).", 
                "measure": "Assessment of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed up to 36 months"
            }, 
            {
                "description": "Immunochemical expression of proteins/messenger ribonucleic acid (mRNA) of the tumor that can be linked to the efficacy / safety of the treatment, the tumor angiogenesis and the mechanism of action of the combination cisplatin/5FU/Afatinib.\nIn bioptic material for gastric or gastroesophageal adenocarcinoma:\nEpidermal Growth Factor Receptor (EGFR) immunohistochemical expression;\nEGFR gene amplification (chromosome 7 gene number by FISH);\nmRNA levels of the EGFR ligands epiregulin and amphiregulin;\nKirsten Rat Sarcoma (KRAS) mutations;\nHuman Epidermal Growth Factor Receptor 2 (HER2) immunohistochemical expression and gene amplification\nHER2 p95, Human Epidermal Growth Factor Receptor 3 (HER3), Human Epidermal Growth Factor Receptor 4 (HER4) immunohistochemical and mRNA expression\nIn peripheral blood and plasma:HER2 shed extracellular domain (ECD)\nThere may be additions to the biomarkers to be analysed, dependent on the clinical and bibliographical data.", 
                "measure": "Value of prognostic and/or predictive biomarkers measured in tissue and blood samples", 
                "safety_issue": "No", 
                "time_frame": "Tumor blocks and blood samples will be collected at baseline"
            }
        ], 
        "source": "Hellenic Cooperative Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hellenic Cooperative Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}